U.S. Plans to Cut 340B Drug Discounts, Boosting Major Pharma Stocks
Miles Bennett
The Trump administration proposed overhauling the federal 340B drug-pricing program from 2027, tying hospital payments to actual acquisition costs — a move projected to save roughly $5.7 billion a year. The VanEck Pharmaceutical ETF (PPH) jumped about 3% on the news, with major drugmakers rallying across the board.
What is the 340B program, and why is the government targeting it?
340B is a federal program that requires drugmakers to sell medicines at steep discounts to eligible hospitals and clinics, so low-income patients can access affordable drugs.
The problem: studies found some hospitals buy drugs at the discount price but charge patients more — the savings never reach the patient; the margin becomes hospital profit.
This means → the program was designed to help patients, but in practice the money leaked to intermediaries.
What does the new proposal actually change?
CMS (Centers for Medicare & Medicaid Services) plans to tie 340B hospital payment rates to actual drug acquisition costs starting in 2027.
In plain terms = hospitals used to buy at a discount and bill at a higher rate, pocketing the spread. The new rule would close that gap.
If finalized, the proposal is projected to save the U.S. roughly $5.7 billion in drug spending as early as next year.
Why did pharma stocks go up on this news?
On the day of the announcement, the VanEck Pharmaceutical ETF (PPH) rose about 3%, hitting its highest level since March. Every constituent stock finished in the green.
AbbVie hit a 52-week high — the company sued the U.S. government in April over how 340B patient eligibility is defined.
This means → big drugmakers have long argued that 340B abuse lets hospitals pocket money that should flow to manufacturers and patients. The government stepping in to tighten the program effectively sides with pharma.
How long have drugmakers and the government been fighting over this?
The dispute is years old. In 2024, Johnson & Johnson and Eli Lilly sued the Department of Health and Human Services over its blocking of rebate-based payment models.
Industry group PhRMA said in June this year that the program's financial incentives increasingly favor large hospital systems and pharmacy benefit managers, while patients, taxpayers, and employers foot the bill.
This reflects a longer pattern: the proposal is not a sudden policy shift but the first clear signal that the government is tilting toward drugmakers' demands after years of standoff.
What does this mean for investors?
The proposal is still at the draft stage. It must go through public comment and final confirmation before taking effect — policy uncertainty remains.
This means → whether this pharma-sector valuation recovery can last hinges on whether the proposal actually becomes final rule.
In plain terms = the good news is already priced in. If the proposal is watered down or shelved, the rally could unwind.
Content is for reference only, not financial advice.